Ghrelin is an orexigenic
peptide involved in the regulation of energy homeostasis. To investigate the role of
ghrelin in the
hyperphagia associated with uncontrolled
streptozotocin-induced diabetes, food intake was followed in diabetic
ghrelin knockout (
ghrelin(-/-)) and control wild-type (
ghrelin(+/+)) mice and diabetic Naval Medical Research Institute noninbred Swiss mice treated with either saline or the
ghrelin receptor antagonist, D-Lys3-GH-releasing peptide-6 (D-Lys3-GHRP-6) for 5 d. In diabetic
ghrelin(-/-) mice,
hyperphagia was attenuated, and the maximal increase in food intake was 50% lower in mutant than in wild-type mice. The increased food intake observed during the light period (1000-1200 h) in
ghrelin(+/+) mice was abolished in mutant mice. Diabetic
ghrelin(-/-) mice lost 12.4% more
body weight than
ghrelin(+/+) mice. In diabetic
ghrelin(+/+) mice, but not in
ghrelin(-/-) mice, the number of
neuropeptide Y (NPY)-immunoreactive neurons was significantly increased. Diabetic Naval Medical Research Institute noninbred Swiss mice were hyperphagic and had increased plasma
ghrelin levels. Treatment with
D-Lys3-GHRP-6 reduced daily food intake by 23% and reversed the increased food intake observed during the light period. The change in the number of NPY- (2.4-fold increase) and
alpha-MSH (1.7-fold decrease)-immunoreactive hypothalamic neurons induced by diabetes was normalized by
D-Lys3-GHRP-6 treatment. Our results suggest that enhanced NPY and reduced
alpha-MSH expression are secondary to the release of
ghrelin, which should be considered the underlying trigger of
hyperphagia associated with uncontrolled diabetes.